Venus Remedies Limited (IN:VENUSREM)
:VENUSREM
Want to see IN:VENUSREM full AI Analyst Report?
VENUSREM Stock Chart & Stats
₹782.25
-₹3.85(-1.26%)
At close: 4:00 PM EST
₹782.25
-₹3.85(-1.26%)
Day’s Range― - ―
52-Week Range₹417.65 - ₹1,802.25
Previous CloseN/A
Volume28.34K
Average Volume (3M)2.33K
Market Cap
₹24.08B
Enterprise Value₹16.93B
Total Cash (Recent Filing)₹2.36B
Total Debt (Recent Filing)₹143.80M
Price to Earnings (P/E)23.4
Beta0.79
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)52.61
Shares Outstanding13,366,988
10 Day Avg. Volume2,529
30 Day Avg. Volume2,330
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.65
Price to Sales (P/S)1.42
P/FCF Ratio9.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)39.9
Revenue Forecast (FY)₹828.20M
Bulls Say, Bears Say
Bulls Say
Diversified Revenue ModelA multi-pronged commercial model (branded formulations, contract/B2B manufacturing, exports and hospital/critical-care sales) diversifies revenue streams and reduces single-channel risk. This supports durable growth opportunities across geographies and customer types over the next 2–6 months and beyond.
Strengthening Cash GenerationMaterial improvement in operating and free cash flow enhances financial flexibility to fund R&D, capex, or working capital without heavy new borrowing. Strong cash generation is a durable fundamental that supports reinvestment and resilience through pharma product cycles.
Conservative Balance SheetLow leverage and steadily rising equity give the company capacity to absorb shocks, pursue targeted M&A or capex, and maintain operations during downturns. A conservatively positioned balance sheet is a lasting advantage for capital allocation and strategic optionality.
Bears Say
Margin Sustainability UnclearSignificant historical gross-margin variability and absence of detailed 2026 margin breakdown make it difficult to assess whether the recent earnings surge is driven by sustainable margin expansion or one-time factors. This uncertainty risks earnings reversals if product mix or pricing shifts.
Choppy Cash ConversionWhile 2026 cash flows improved, prior years show inconsistent conversion of profit to cash, implying volatile working capital or capex timing. Persistent variability can constrain consistent free cash generation and limit the company’s ability to fund growth or repay debt sustainably.
Revenue Lumpy From Tender/B2B ChannelsHeavy exposure to tenders and contract manufacturing creates volume and pricing volatility and higher customer-concentration risk. Winning and renewing tenders/contracts is competitive and cyclical, which can produce lumpy revenue and pressure margins over medium-term horizons.
Venus Remedies Limited News
VENUSREM FAQ
What was Venus Remedies Limited’s price range in the past 12 months?
Venus Remedies Limited lowest stock price was ₹417.65 and its highest was ₹1802.25 in the past 12 months.
What is Venus Remedies Limited’s market cap?
Venus Remedies Limited’s market cap is ₹24.08B.
When is Venus Remedies Limited’s upcoming earnings report date?
Venus Remedies Limited’s upcoming earnings report date is Aug 18, 2026 which is in 64 days.
How were Venus Remedies Limited’s earnings last quarter?
Venus Remedies Limited released its earnings results on May 26, 2026. The company reported ₹35.53 earnings per share for the quarter, beating the consensus estimate of N/A by ₹35.53.
Is Venus Remedies Limited overvalued?
According to Wall Street analysts Venus Remedies Limited’s price is currently Overvalued.
Does Venus Remedies Limited pay dividends?
Venus Remedies Limited pays a Annually dividend of ₹3 which represents an annual dividend yield of N/A. See more information on Venus Remedies Limited dividends here
What is Venus Remedies Limited’s EPS estimate?
Venus Remedies Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Venus Remedies Limited have?
Venus Remedies Limited has 13,366,988 shares outstanding.
What happened to Venus Remedies Limited’s price movement after its last earnings report?
Venus Remedies Limited reported an EPS of ₹35.53 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.339%.
Which hedge fund is a major shareholder of Venus Remedies Limited?
Currently, no hedge funds are holding shares in IN:VENUSREM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Venus Remedies Limited
Venus Remedies Limited is a pharmaceutical enterprise engaged in the development, production, and global distribution of its medicinal products, serving both the Indian and international markets. The company's diverse portfolio addresses a wide spectrum of therapeutic areas, including treatments for pain and fever, diabetes, bacterial infections, cardiovascular conditions, gastrointestinal disorders, neurological ailments, and oncology. Additionally, it provides solutions for respiratory health, skin and wound care, stress management, and urological issues, alongside essential vitamins, minerals, and nutritional supplements. Venus Remedies is also active in the field of antimicrobial resistance, offering specialized products, and it supplies disinfectants and hand sanitizers. Furthermore, the firm maintains a distinct line of herbal products and offers hormones and iron supplements. Established in 1989, Venus Remedies Limited operates from its headquarters in Panchkula, India.
Technical Analysis
Indoco Remedies Limited
―
Ind-Swift Laboratories Ltd.
―
Lincoln Pharmaceuticals Ltd
―
Syncom Formulation (India) Ltd.
―
Windlas Biotech Ltd.
―